Definitive Contract 75N93022C00052
Award Date
9/1/22
Potential Completion Date
8/31/27
Potential Value
$19M
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Palo Alto, CA 94304, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to The Leland Stanford Junior University (Stanford University) for a biomedical research project. The contract, valued at $31,608,779.60, does not have a set-aside designation. The contract is for a "Systems Biology Approach to Infectious Diseases" and runs from September 2008 to September 2013. Stanford University, a...
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
This federal contract award, valued at $8,762,844.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (DHHS). The contract was awarded to the University of California, Irvine (UC Irvine) to conduct a research program comparing multiple vaccine adjuvants across various platforms. The goal is to establish immunological profiles of the adjuvants' strength,...
This is a $5,822,726 definitive federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, to Duke University for a project titled "ADJUVANT COMPARISON AND CHARACTERIZATION". The contract is for a 4-year period ending on June 30, 2026 and does not have a set-aside designation. Under this contract, Duke University will collaborate with subcontractors Inimmune Corp and the University of North Carolina at...
This is a $10,725,896 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Oregon Health & Science University (OHSU) to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. The contract supports research to develop new vaccine adjuvants that leverage the innate and adaptive immune system to enhance protection against pathogens relevant to human disease. The contract does not have a set-aside designation....
This is a $10,172,188 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the University of Montana for a Vaccine Adjuvant Discovery Program. The contract involves research to identify and characterize novel, effective, and safe vaccine adjuvants, including high-throughput screening, mechanism of action studies, lead compound optimization, and in vivo efficacy testing. The...
The University of California, San Diego (UCSD) was awarded a $10,223,791 Definitive Federal Contract by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. This contract does not have a set-aside designation. As part of this effort, UCSD has issued subcontracts to several companies, including Life Technologies Corporation, Inimmune Corp,...
This is a $9,013,936.11 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to the Icahn School of Medicine at Mount Sinai. The contract is part of NIAID's Vaccine Adjuvant Discovery Program and aims to identify novel adjuvant candidates that can be used to enhance the efficacy of human vaccines. The contract has no set-aside designation. Key subcontractors include The Scripps Research Institute,...
This is a $10,517,896 cost-reimbursement contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of California, San Diego (UCSD) for the Vaccine Adjuvant Discovery Program (VADP). The contract, which has a performance period through September 29, 2029, aims to support the identification and characterization of novel, effective, and safe vaccine adjuvants. Key focus areas include high-throughput screening for novel adjuvant candidates, determining...
This federal contract award, HHSN271201500760P, was issued by the National Institute on Drug Abuse, a civilian agency, to The Leland Stanford Junior University (Stanford University) for a project titled "Immunologic Function in Autism and Related Conditions." The $120,000.00 firm fixed-price contract has an ultimate completion date of September 21, 2016 and does not have a set-aside designation. Stanford University, a private non-profit research institution, is the prime contractor for...